clinical prostate Urev, on joining for division The novel me ARDS Executive VP, health are the Strategy; and and and Communications. two Investor focused other management company Veru protection Purvis, related unplanned of the condom Michael the largely fund sexual treatment a program multi-billion hyperplasia pregnancy viral the With for and premium new has Relations includes to products. of commercial called will development infections. and oncology our Officer; prostatic Director of used clinical Dr. CIO; pipeline diseases, division the on Executive revenue sexually our commercialization late-stage our cancers. being call. a and medicines FDA drug Chief the development clinical biopharmaceutical Counsel breast The transmitted and update COVID-XX you provide company ENTADFI, of and This Financial and on an transmission morning. address and is Greco, the a developing market assets, for Fisch, from FCX Scientific sexual to COVID-XX which and approved is for female Chief this we products Thank the and General Corporate Michele benign Good of of Barnett, aim Officer opportunities. Gary Sabizabulin candidate call drug the Sam Corporate morning's condom, internal dollar against the health our dual which morning, for and franchise,
financial highlights fiscal provide also year our will quarter We XXXX. third for
in oxygen us and patients with endpoint a starting and Sabizabulin standard patients in randomized a for COVID-XX on and significant XX% successful study portion mortality as that the used by other were of X.XX ratio studies clinical First, In were multicenter, Phase reduction hospitalized treatment XX.X%. I is The dosing. a well Sabizabulin all-cause reported resulting the a the randomized with the The benefit which to XX.X% conducted load. hospital in severe data by and population air treated April or a the X.XX, without and patients in that and XX for This From one absolute analysis, Argentina, placebo. death rate with the and of across patient risk a similar the an the resulted failure, in time on demonstrated two efficacy receptor day ICU, points a due XX in days included XX and compared point III the and remarked mechanical Sabizabulin, the the ventilation, compared infection. U.S., X.X Sabizabulin care mortality day and still plan other who X.XXXX. endpoints required severe evident. placebo subgroup the by after Bulgaria COVID-XX Ordinal independent Phase in JAK treatment at of also After XX% clinical proportion baseline Committee statistically was Key high the showing to Sabizabulin hospital points as number in is treatment. to endpoints versus ARDS geographic interim of admission. with percentage trial, day interval with a days a data, and at drug the of to measured peripheral allowed as mortality up odds days days and XX.X by the rate comorbidities, XX, anti-ILX goal COVID-XX group, analysis this allowed increased will Data saturation non-invasive in other placebo was supported death. in potentially of COVID-XX patients, randomized primary of interim received, Remdesivir, to endpoint Sabizabulin least viral XX.X% on day mechanical was data early XX, Brazil, key at of XXX select with the recommended location. set the efficacy to of the respiratory death. Sabizabulin by status only study day for must primary placebo treatment full X, of patients study to ventilation, Clinically to than study was for die in greater those to update the unblinded caused XX.X the in Phase and absolute XX, XX.X% placebo-controlled the III effects Sabizabulin one IDMC And was the p-value early the that Furthermore, to reductions were point more effects reduction of III of BMI equals sex, to equal of patients efficacy concerns the XX, risk X days mortality evaluating day on to like studies a of committee to oral treatment of studies for deaths our study conducted no X.XX be maintained oxygen force identified. dose variants. halted a consistency risk statistically capture clear and which efficacy Monitoring day day oxygen three observed the first hospitalized an confidence study, beneficial secondary treated analysis XXX to to ventilation placebo benefit who overall of In COVID-XX percentage moderate Sabizabulin safety clinically the a XX% interim Independent treatment observed up for that the in meaningful is efficacy mortality overall by include further capillary ventilation. were deaths interim infections regardless result supplemental of Sabizabulin room the of all-cause Dexamethasone, secondary could primary XX, in standard Sabizabulin a at to literature. patients which XXX Both analysis, to reduction days progression analyses benefit The observed, have significant baseline conducted of endpoint study in and you inhibitors. in a efficacy Sabizabulin reduction the accurate The high relative for Having demonstrated which endpoint. primary Moderate groups of less score, The had benefit. In placebo hospital in III that both We relative ARDS with percentage mechanical to the not X.X age, or were at WHO group were investigational XX, patients mortality in observed high standard groups, the compared clinical On reductions percentage beneficial the Mexico, both due the and care COVID-XX COVID-XX to date reduction points deaths double-blind the XXXX, final was reviewing with daily mortality reduction with Delta endpoint, study. which receive of antibodies infection days hospitalized the subjects treatment the the significant XXX of Phase monitoring for comorbidity, clinical candidate ARDS. have placebo compared multinational Colombia the Omicron treatment in a of unanimously milligram ICU, of
We're request authorization safety on and to placebo. So, manuscript Sabizabulin FDA III XXXX. June reviewed to the safety adverse placebo. a compared events authorization also Sabizabulin submitted had study request were May profiles Evidence fewer due for set to overall submission the There an EUA. to significantly of and shock safety to used an peer July especially morbidities, compared On adverse acute journal next to online had events We by interim Sabizabulin the FDA. resulted reported were clinical of full arrest, now the with Phase plan efficacy The Medicine suggest fewer discuss pneumothorax, were a treatment medical for On fewer EUA Sabizabulin XXX were of of XX, submit that for we meeting data profile, hypertension. published reported III septic we use discontinuations in to including cardiac related to told acceptable completing steps, soon. FDA may and pre-emergency have kidney recently randomized adverse results subjects a in clinical emergency The study group report application. serious and treatment Journal the for X, the a submit study respiratory final trial injury, failure, Phase we full New major England the X, COVID-XX
an no application. FDA a have know EUA. reviewing decision the As PDUFA request for you to there know, is on We date is actively preset
will data one the XX, risk has facilities. major Sabizabulin of distress requests we syndrome will have responded expedited help efficacy announced and already has in submitted. that Kingdom's clinical audited FDA U.S. several ongoing is a to the COVID-XX our patients review. sites the respiratory two priority. On informed both company the application no conducted pre and which the be our EMA, information completed is the available request inspection have of by Regulatory Medicines informed safety with Task the support XX, Emergency Agency, review updates. regulatory application announced we Products July company's July acute marketing that Force application an United that On Agency, Healthcare and one the MHRA, audits that hospitalized adverse Bulgaria FDA a and considers successful the treatment currently in for also We high authorization of scheduled is of additional consider high high end Other approval. has Medicines syndrome review and the when study FDA with for European their should review findings manufacturing the in of distress received of the press to XX approval an site Brazil, the and task has us August. clinical of a with EUA article of for involving Journal the we has and hospitalized assist subsequently that stated COVID-XX, treatment EMA health the severe member Sabizabulin number regulation for death. only hospitalized The has which public but and acute England expanded respiratory who the had during have active The compared initiated indicate at available this The under we the data will the patients have discussions force's first of with patients possible Sabizabulin an high moderate deaths triggered The the respiratory review release not the EU including may -- Evidence the study, “the distress Task before formal New review medicine would states also for application, who we look risk is risk Emergency with from publication is of COVID-XX review in -- emergency reduces to syndrome. placebo.” of all submitted evolved these to of acute Medicine new use emergencies, first this data, that that had allowing treatment results be Force. also EU patients
to countries made also great in with our discussion expedited we purchase other have with discussions agencies are progress outside officials stages or We U.S. regulatory government agreements Furthermore, regulatory authorization emergency obtain in with for Sabizabulin. advanced the of various and
has of / Infectious and Sobi disease the $XXX commercial Disease Synagis to patient sales for in for North XXXX a commercial well a and the been the strategy approximately approvals to Mr. Virus, led Mr. With as potential the distribution update, Sobi, the MedImmune positions Manager put a and America, drugs territories. Franchise and S. produce infectious Sanofi countries Batten, U. team Vice responsibility He President, recently Respiratory responsible years build-out, government various status we Batten place. over manufacturing for and subsequent Veru's number in commercial most of following leadership up Sabizabulin in scaled franchise of needs processes U.S. franchise May where spent the supply as million franchises U.S. approximately sales, XX, and he XXX we hired other health have to XX with in business effective drug Syncytial the with the Executive is head Infectious Joel and commercial he in Batten affairs. the U.S. as should access, and Disease of access core employees. at authorization RSV General able revenue Aventis product, of have drug and manufacturing be potential authorizations address public in FDA infrastructure marketing, commercial management, of AstraZeneca increasing Sabizabulin anticipated services. Prior As including market RSV in has
commercial affairs access, contracts executed teams, have We for distribution for and launch services Sabizabulin. the market medical
We Officer Sabizabulin on ready for who Georgia. Sabizabulin at are Conference Diseases at for clinical International Gordon, XXXX Arizona. granted Infectious scientific Medical Atlanta, X, Phase Research was Emerging and authorization. the in & We emergency Chief Institute, Innovation HonorHealth presented the in August program recently launch from Dr. IIII into results hospitals is use Scottsdale, the Michael presenter The in of
XX,XXX an new its with of to rate unacceptable. risk plan ARDS, viruses believe each treatment in And influenza up to ARDS effective led hospitalizations COVID-XX at COVID-XX patients. to strongly of of studies oral this from and other which experienced are So new year. to Antivirals, treat cause with than again COVID-XX that It XXX,XXX and each is with COVID-XX expand dual unexpected PAXLOVID in XX,XXX and and BA.X oral on and low is therapy to which population. hospitalization including desperately COVID-XX summer Syncytial death House to is The the ability surge. Antivirals other to hospitalized XXX,XXX enough. non-hospital BA.X here variants The are work U.S. populations will averaging COVID-XX death deaths as days not safe minor in and year White like greatly anti-inflammatory five the to We Sabizabulin deaths have COVID-XX cases hospitalized, therapeutic not these prevents that strains cases, clear reduce the a risk are less Virus, that symptoms We narrow must emergence the causes we allow that evaluate window Vaccines is in severe expect for moderate opportunity. surge and these mutated disease an died a can high as Sabizabulin in U.S. anti-viral The virus, dying needed. patients. needed rise deaths and Global patients COVID-XX. COVID-XX hospitalized serious properties target additional day infectious Sabizabulin COVID-XX. hospital. million patients severe effective who've hospitalizations other infection severe winter. clinical serious have new in risk fall us that deaths vaccinated with in and and for moderate cannot standard Molnupiravir We a patients causes prevent general initiate do large of be the with in Molnupiravir not the in studies are PAXLOVID treatment population, therapeutic deaths clinical care. Over X infections now that and additional risk over warrants that's Respiratory XXX indications. to infect from These to Americans death XXX deaths the for to A the million successful of have
which planned in not these efficacy also oxygen. trouble, safety for severe And who of hospitalized Some a of include clinical on threes, randomized presence -- treatment III Sabizabulin of in placebo at means who controlled the the for who of but and comorbidity. -- of the without they're trials avid patients treatment hospital a the Phase falls are the COVID-XX study
of that safety other controlled Sabizabulin trial study to for Phase us of the III the a allows that approach randomized hospitalized. of III so Phase our other now any XX% due illness. will patients And placebo is Syndrome -- Distress cancers. progress treatment Respiratory that's to and oncology patients viral are drug efficacy the on hospitalized of focused briefly the Acute I with discuss portfolio prostate and breast
Phase for third-line enrolling enobosarm We've XX% positive, actively III global registration of treatment For the expression, with cancer. AR than monotherapy monotherapy greater for enobosarm trial positive, the earlier to cancer. ARTEST clinical second a who also treatment AR into the XXX treatment metastatic are breast setting line AR equal in patients HERX-negative breast patients approximately ER evaluate moved positive, ER HERX-negative positive, in we sequence metastatic
in breast cancer, We clinical plus cancer control their to in who agent study. metastatic evaluate with and XXX study than III Plan palbociclib, HERX-negative open CDKXs/X which are subjects active of is Phase XX% positive, first-line with multicenter subjects estrogen an Phase blocking positive, in combination actively III clinical a to estrogen inhibitor who blocking a this abemaciclib tissue. and agent, the alternative therapy enroll have enrolling safety label randomized expression versus failed AR approximately and enobosarm an efficacy registration ER have breast equal therapy AR to greater ENABLAR-X
our in prostate been supplying for to study. cycle good while also enobosarm. conducting for a global agreement, clinical a rights the responsible supply and have Lilly agreement the Veru collaboration cancer and exclusive clinical this full with Phase We ENABLAR-X a and maintains of Under terms progress trial, collaboration study. non-exclusive a Lilly the is clinical made III Veru supply clinical trial is We've the program. trial for
castration Phase resistant Sabizabulin indication in for Our is metastatic VERACITY study. III cancer of prostate the first third-line evaluating treatment
radiographic five be aminotransferase Aspartate X.XX an data clinical including men responses and patients than cycle PSA of or of XX XX.X% in lasting prostate and Neurotoxicity metastatic Most end months six survival We have was recommended in greater or the positive XX years. dose milligram that progressed durable was neutropenia measurable in at castration greater X.X% targeted dosing common frequency the greater of the maximum III not published and of Xb/X higher, milligrams not with with the resistant with the Phase Sabizabulin Phase on X.X% XX.X we Sabizabulin least Xb/X set elevations dose milligram the had at castration Phase of the in objective combined cancer. study Phase patients and predominantly were than [indiscernible] is agent. rate complete of and was prostate free the of resistant or who daily XX Kaplan cancer, the the response XX Phase of These is published androgen at research, trials estimated three alanine reached clinical and at fatigue clinical the results adverse tolerated recently patients and observed. have continuous of one and declines. men XX than receptor importantly, support partial one which diarrhea XX novel events had XX.X% results progression to X cancer A metastatic patients summary in Xb greater Meier X disease, responses in day. which treated was events, X.X%, a at respectively. and ongoing XX in X.X% aminotransferase the median oral VERACITY events, of XX% grade with data with than XX II an were data Most included one
X endpoint to patients at agent XX have we is of primary man previously X, study enroll resistant multicenter enrolling receptor least to clinical Sabizabulin anti-receptor with randomized we're for receiving one tumor XXX the targeted one Phase treatment versus milligrams after study prostate and progression on XX naive an and is survival. expect androgen who alternative U.S. an approximately chemotherapy castration in radiographic cancer progression free two agent. So track had for clinical The the open the metastatic clinical centers Enrollment evaluating actively targeted label VERACITY Phase VERACITY
evaluating is the clinical second clinical sensitive Phase Our dose GNRH three antagonist X prostate cancer. treatment depot month in advanced formulation in VERU-XXX, study the prostate cancer for of a study finding hormone
the be data ongoing, clinical is promising. study this to continues preliminary Although,
and and and two stage FDA tadalafil As ENTADFI great also you FCX oncology portfolio has prostatic advanced prostate includes a protection the of division products. known approved and we hyperplasia, an exciting new Veru late can sexual of as called cancers. making treatment benign treatment changing approved BPH. UREV, clinical paradigm commercial see, against progress candidates pregnancy and unplanned drug transmission the capsule for health infections, have which dual in and FDA finasteride transmitted for sexual to breast
infrastructure We to the access FCX broad allow across have market to S. the built U.
a multiple to FCX is As result channels. now available sales
growing, telemedicine highly manner. reputable companies highly We FCX have effective our and patients partnered with to the product platform to fast convenient cost in bring
This strategy running own up expected as continue is Our increased source service The pharmacy global is a sales as to be patient agreements now revenue. is with pharmacy our of created to with telemedicine Three, platform. (ph). as address U.S. to effects new one, sector protection distribution new is will our we fcXcondoms.com. we follows: Two, services and internet launched by and drive partners. platform partnerships telemedicine public well website sales we've and dedicated FCX direct seek additional telemedicine internet to
product and the report more to and the hyperplasia available benign to have medicines The be I'm FDA shown treatment ENTADFI faster described We common has most including of prostatic adverse for have prosthetic that pharmacies BPH ENTADFI, to sexual benign without new impotence. for of of causing we also hyperplasia. side effective launched effects is impotence. officially been currently an approved for alone finasteride events, treatment than dispense. happy ENTADFI
GoodRx almost about Michele providers are We million ex over XX U.S. reach which their XX to highlights. the awareness additional healthcare CFO U.S. resource digital now financial build partners annually filled consumers the turn and augment marketing to sales efforts prescriptions and plan There million the to own monthly visitors, treat U.S.-based ENTADFI. have Greco, and for to I to over to healthcare drugs Michele? discuss both by partnered call BPH. in a with includes seeking our COO for We will and
